TY - JOUR
T1 - Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors
AU - Rossi, Antonella Russo
AU - Breccia, Massimo
AU - Abruzzese, Elisabetta
AU - Castagnetti, Fausto
AU - Luciano, Luigiana
AU - Gozzini, Antonella
AU - Annunziata, Mario
AU - Martino, Bruno
AU - Stagno, Fabio
AU - Cavazzini, Francesco
AU - Tiribelli, Mario
AU - Visani, Giuseppe
AU - Pregno, Patrizia
AU - Musto, Pellegrino
AU - Fava, Carmen
AU - Sgherza, Nicola
AU - Albano, Francesco
AU - Rosti, Gianantonio
AU - Alimena, Giuliana
AU - Specchia, Giorgina
PY - 2013/3/1
Y1 - 2013/3/1
N2 - There have been few reports of a response to dasatinib or nilotinib after failure of two prior sequential tyrosine kinase inhibitors. We report the outcome of 82 chronic phase patients who received nilotinib or dasatinib as third-line alternative tyrosine kinase inhibitor therapy. Thirty-four patients failed to respond to nilotinib and were started on dasatinib as third-line tyrosine kinase inhibitor therapy while 48 patients were switched to nilotinib after dasatinib failure. Overall, we obtained a cytogenetic response in 32 of 82 patients and major molecular response in 13 patients; disease progression occurred in 12 patients. At last follow up, 70 patients (85.4%) were alive with a median overall survival of 46 months. Our results show that third-line tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients after failure of two prior sequential tyrosine kinase inhibitors may induce a response that, in some instances, could prolong overall survival and affect event-free survival.
AB - There have been few reports of a response to dasatinib or nilotinib after failure of two prior sequential tyrosine kinase inhibitors. We report the outcome of 82 chronic phase patients who received nilotinib or dasatinib as third-line alternative tyrosine kinase inhibitor therapy. Thirty-four patients failed to respond to nilotinib and were started on dasatinib as third-line tyrosine kinase inhibitor therapy while 48 patients were switched to nilotinib after dasatinib failure. Overall, we obtained a cytogenetic response in 32 of 82 patients and major molecular response in 13 patients; disease progression occurred in 12 patients. At last follow up, 70 patients (85.4%) were alive with a median overall survival of 46 months. Our results show that third-line tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients after failure of two prior sequential tyrosine kinase inhibitors may induce a response that, in some instances, could prolong overall survival and affect event-free survival.
UR - http://www.scopus.com/inward/record.url?scp=84874514362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874514362&partnerID=8YFLogxK
U2 - 10.3324/haematol.2012.064337
DO - 10.3324/haematol.2012.064337
M3 - Article
C2 - 22801965
AN - SCOPUS:84874514362
VL - 98
SP - 399
EP - 403
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 3
ER -